ISRCTN16859029已完成2 期
A Two-part Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Applications of Four Transdermal Patch Formulations of Hyoscine and Physostigmine in Healthy Male Participants
Defence Science and Technology Laboratory (Dstl)0 个研究点目标入组 24 人开始时间: 2019年9月19日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •At screening for period 1:
- •1. Ability to give written informed consent prior to study participation
- •2. Healthy Caucasian male participants aged between 18 and 45 years (inclusive)
- •3. Body Mass Index (BMI) within the range of 21 and 30 kg/m2
- •4. Vital signs within the following ranges:
- •4.1 Pulse rate 40-90 bpm
- •4.2 Systolic blood pressure 90-140 mmHg
- •4.3 Diastolic blood pressure 50-90 mmHg
- •5. Ability to communicate well with the Investigator and to comply with the requirements of the study.
- •Baseline (Period 2):
- •1. Successful completion of Part 1.
- •2. Randomisation to take part in Part 2.
- •3. Willing and able to continue in the study.
排除标准
- •Does not meet inclusion criteria
研究者
相似试验
进行中（未招募）
1 期
A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children with Duchenne Muscular DystrophyMedDRA version: 14.1Level: SOCClassification code 10028395Term: Musculoskeletal and connective tissue disordersSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersDuchenne Muscular DystrophyEUCTR2012-002566-12-ITITALFARMACO20
已完成
1 期
A programme to develop a skin patch containing two medicines (physostigmine and hyoscine), study 5: Assessment of blood levels of the two medicines and any associated symptoms in healthy male participantsISRCTN79173829Defence Science and Technology Laboratory30
已完成
1 期
Assessing in a sequential manner, the safety, tolerability and pharmacokinetics of multiple formulations of CTP-730 in healthy volunteersACTRN12615000511538CPR Pharma Services22
已完成
不适用
*A Two Part Phase I Study to Assess Safety, Tolerability, Systemic Exposure and Effect on Analgesia and Anaesthesia of Single and Multiple doses of TDT 077 in Healthy Older Subjects.*Neuropathic pain10034606NL-OMON31518Celtic Pharma Development Services Europe Ltd.96
进行中（未招募）
1 期
A study exploring the safety, tolerability, and efficacy of INCAGN01876 in combination with immune therapies in subjects with advanced or metastatic malignancies.Phase 1: advanced or metastatic cervical cancer, endometrial cancer, gastric cancer, hepatocellular carcinoma, melanoma (mucosal or cutaneous), Merkel cell carcinoma, mesothelioma, MSI-H colorectal cancer, non–small cell lung cancer, ovarian cancer, squamous cell carcinoma of the head and neck (SCCHN), small cell lung cancer, renal cell carcinoma, triple-negative breast cancer, and urothelial carcinoma (or others). Phase 2: advanced or metastatic endometrial cancer, gastric cancer, and SCCHNMedDRA version: 20.0Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10014733Term: Endometrial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027407Term: Mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000017553MedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027150Term: Melanoma malignantSystem Organ Class: 100000018529MedDRA version: 20.0Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 100000018548MedDRA version: 20.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignaEUCTR2016-004989-25-ESIncyte Biosciences International Sàrl145